Search
Prucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880] … [A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.
Categories: Drugs for ConstipationLasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnIt was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA. … It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment of vaginal atrophy.
Bismuth subnitrate
go.drugbank.com/drugs/DB13209ApprovedWithdrawnBismuth subnitrate, also referred to as bismuth oxynitrate or bismuthyl nitrate, is a highly water-soluble crystalline compound that has been used as a treatment for duodenal ulcers and anti-diarrheic … The use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA.
Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)CX-046684
go.drugbank.com/drugs/DB19414ApprovedCX-046684 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage KP.2. … It is the active ingredient of the 2024-2025 formulation of Moderna's Spikevax vaccine.[L40074]
Gemifloxacin
go.drugbank.com/drugs/DB01155ApprovedInvestigationalIt is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth. … Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseRupatadine
go.drugbank.com/drugs/DB11614ApprovedInvestigationalIt was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and liquid formulation for pediatric use. … Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria
Categories: Antihistamines for Systemic Use, Histamine H1 Antagonists, Non-SedatingZolpidem
go.drugbank.com/drugs/DB00425ApprovedInvestigationalIt is aimed for use in patients with difficulties initiating sleep. … Research also shows that zolpidem is rapid and effective in restoring brain function for patients in a vegetative state following brain injury.
Synonyms: N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamideMacimorelin
go.drugbank.com/drugs/DB13074ApprovedThey include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. … Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.
Categories: Tests for Pituitary FunctionEflapegrastim
go.drugbank.com/drugs/DB15001ApprovedInvestigational[L43135] Eflapegrastim is a form of recombinant human G-CSF comprising a human G-CSF analog coupled to the Fc fragment of human IgG4 via a polyethylene glycol linker. … The primary factor associated with FN risk is the chemotherapy regimen being administered - regimens are classified as either high-, intermediate-, or low-risk for FN, and relevant guidelines recommend
Selumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigational[A193611] However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumours in Phase II trials … [A193611] "The novel MEK 1/2 inhibitor, selumetinib, was initially approved solely for the treatment of pediatric patients with Neurofibromatosis type 1 (NF-1) and symptomatic, inoperable plexiform